Michael Richard, MD
Ophthalmology · Durham, NCNPI 1669434197
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,569 of the $112,573 with a category attached, or 80.5%. Amgen accounts for 98.5% of it on its own, with 8 other manufacturers making up the rest. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $461.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$111K
- AbbVie$935
- Galderma Laboratories, L.p.$325
- Revance Therapeutics, Inc.$165
- Bausch & Lomb, A Division Of Bausch Health US, LLC$100
- Tarsus Pharmaceuticals, Inc.$55
- plus $67 from 3 others
What the payments were for
- Consulting fees$6,3006%
- Speaking & faculty fees$90,56980%
- Travel & lodging$9,7559%
- Food & beverage$5,9405%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 168 | $110,926 |
| AbbVie(2 entities) | 41 | $935 |
| Galderma Laboratories, L.p. | 16 | $325 |
| Revance Therapeutics, Inc. | 11 | $165 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Tarsus Pharmaceuticals, Inc. | 3 | $55 |
| Dompe US, Inc. | 2 | $33 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Argenx US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,573 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 148 | $1,604 |
| Prednisolone Acetate | 37 | $1,110 |
| ErythromycinErythromycin Base | 81 | $841 |
| Cromolyn Sodium | 52 | $821 |
| Doxycycline Hyclate | 38 | $597 |
| Mometasone Furoate | 30 | $547 |
| Prednisone | 22 | $169 |
| ValacyclovirValacyclovir Hcl | 11 | $140 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Durham
- Julie WoodwardDurham$1M
- Lejla VajzovicDurham$681K
- Terry KimDurham$605K
- Leon HerndonDurham$230K
- Glenn JaffeDurham$218K
- Robin VannDurham$213K
- Anthony KuoDurham$186K
- Priyatham MettuDurham$111K
- Jason LissDurham$69K
- Majda HadziahmetovicDurham$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.